Home › Trials › NCT07838415
Clinical trial Recruiting at 1 site Observational Ages 18 to 80

MRI plus diffusion and CEST imaging to map liver cancer and its immune environment

Official title: Multimodalomics-based Construction of Spatiotemporal Characteristics of Dynamic Liver Cancer Microenvironment to Characterize the Clinical Application of Immune Mechanisms in Liver Cancer

Run by Tongji Hospital · NCT07838415 · Data updated 2026-11-12

This study tests whether adding an extra MRI sequence can help see how the liver cancer microenvironment changes and relate those changes to immune activity in patients with hepatocellular carcinoma.

Quick facts

Study typeObservational
Ages18 Years to 80 Years
SexAll
Enrollment400 (estimated)
SponsorTongji Hospital
Academic / other
Locations1 site (Wuhan, Hubei)
StatusRecruiting
StartedOctober 1, 2024
Main results expectedJune 2027
Study endsJune 2028
Registry record updatedSeptember 24, 2026
Trial IDNCT07838415 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults 18 years and older with pathologically confirmed hepatocellular carcinoma and available Td-dMRI-inclusive EOB-MRI within 1 month before surgery.

Probably not a fit

Patients with lesions smaller than 1 cm, poor imaging quality, or those who have received other treatments prior to surgery may not benefit from the study insights.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Researchers will prospectively enroll adults with suspected or confirmed hepatocellular carcinoma who are undergoing routine liver MRI. In addition to the standard MRI protocol, each participant will receive one extra time-dependent diffusion MRI and a CEST sequence. Imaging features from the extra sequence will be combined with clinical data to build a multi-omics model aimed at capturing dynamic tumor microenvironment changes that reflect immune mechanisms. The goal is to identify imaging biomarkers that could aid in diagnosis and guide clinical management of liver cancer. This is an observational study seeking correlations between imaging signals and clinical-pathology data.

Why it matters

Potential benefit: If successful, the study could provide imaging biomarkers that help tailor diagnosis and treatment choices for liver cancer patients.

How similar studies have gone: Prior studies using advanced MRI and multi-omics approaches have shown promise in characterizing tumor microenvironments, though this exact sequence combination is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

1. age 18 years or older, (b) pathologically confirmed HCC with available pathology slides, and (c) EOB-MRI including Td-dMRI within 1 month before surgery.

Exclusion Criteria:

* (a) lesions smaller than 1 cm, (b) poor imaging quality, and (c) received other treatments before surgery.

Where it's running

  • Tongji Hospital
    Wuhan, Hubei, China     Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Hepatocellular Carcinoma (HCC) 119Treatment Response 3Tongji Hospital 160
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.